Duodenal Patents (Class 514/926)
-
Patent number: 5648092Abstract: The invention relates to pharmaceutical compositions in the form of pleasant-tasting chewable tablets or chewable coated tablets which, besides the pharmaceutically active ingredient sucralfate, essentially contain at least one rapidly swellable physiologically acceptable gel former plus sugars or sugar substitutes.Type: GrantFiled: July 19, 1991Date of Patent: July 15, 1997Assignee: Merck Patent Gesellschaft Mit Beschrankter HaftungInventors: Hans Peter Weckenmann, Hans-Gunther Schwamb
-
Patent number: 5620964Abstract: A composition for treating and/or inhibiting gastric and duodenal ulcers, comprising an oligosaccharide selected from the group consisting of Formula I ##STR1## or a mixture thereof; wherein:X is independently OH or NHAc;Y is independently H, or an amino acid or a peptide of 2-100, preferably 2-20, amino acids; andW, W', and W" are each independently H or ##STR2## where Z is independently H or a pharmaceutically acceptable cation; and P is independently H or ##STR3## where Z is defined as above; wherein at least one of W, W' or W" is an .alpha.-N-acetylneuraminic acid moiety, andwherein W' and W" are not simultaneously .alpha.-N-acetylneuraminic acid moietywith the proviso that the compound of Formula II is not NAN .alpha.(2.fwdarw.3)Gal .beta.1-4 Glu or NAN .alpha.(2.fwdarw.6)Gal .beta.1-4 Glu; and a kit for detecting the presence of Helicobacter pylori comprising at least one compound of the Formula I or II, are described.Type: GrantFiled: June 5, 1995Date of Patent: April 15, 1997Assignee: Neose Technologies, Inc.Inventors: Stephen Roth, Edward J. McGuire, Dennis H. Langer
-
Patent number: 5618564Abstract: The present invention is directed to a method for the treatment of Helicobacter pylori infection wherein a composition containing protease and an antibacterial agent as active ingredients, which can remove Helicobacter pylori from a stomach at high probability without causing side effects or the occurrence of resistant bacteria, and which can treat and prevent peptic ulcer caused by Helicobacter pylori infection and can prevent the recurrence of peptic ulcer is employed.Type: GrantFiled: July 27, 1995Date of Patent: April 8, 1997Assignees: Ken Kimura, Kaken Pharmaceutical Co., Ltd.Inventors: Ken Kimura, Yushi Taniguchi, Kiichi Satoh, Kouji Saifuku, Ken Kihira, Kenichi Ido, Yukio Yoshida, Takuya Takimoto
-
Patent number: 5578576Abstract: The present invention provides a method for aiding healing or preventing the onset of intestinal wounds or ulcers in a patient. In addition, the present invention provides a method for reducing, or preventing, the gastrointestinal side effects associated with the administration of a nonsteroidal anti-inflammatory drug. Pursuant to the present invention, the composition includes a protein source, a carbohydrate source, a fat source, and a specialized vitamin and mineral profile.Type: GrantFiled: September 2, 1994Date of Patent: November 26, 1996Assignee: Dalhousie UniversityInventor: Desmond Leddin
-
Patent number: 5560912Abstract: The invention relates to the use of an organic extract of the plant Cinnamon or a chemical constituent present in said plant, to prepare a pharmaceutical composition useful to inhibit the growth of Helicobacter pylori and the urease activity of Helicobacter pylori. Most preferred chemical constituents are cinnamaldehyde and methoxycinnamaldehyde. The extract may be used either as a drink, with or without additional flavoring ingredients or transformed into a capsule. The invention also relates to in-vitro method for determininig the inhibition of urease activity of Helicobacter pylori using said organic extract of the plant or chemical constituents present in said plant.Type: GrantFiled: June 27, 1994Date of Patent: October 1, 1996Assignee: Technion Research & Development Foundation Ltd.Inventors: Itzhak Neeman, Mina Tabak, Robert Armon
-
Patent number: 5559109Abstract: A method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma, inflammation or shock by administering an effective amount of a PAF antagonist of the formula ##STR1## wherein R.sup.1 and R.sup.2 are each --R.sup.5, --CH.dbd.CH--R.sup.5 or --C.tbd.C--R.sup.5 ; R.sup.5 is an unsubstituted or substituted C.sub.6 -C.sub.14 carbocyclic aryl of an aromatic heterocyclic having from 5 to 14 ring atoms, of which from 1 to 5 are hetero-atoms selected from the group consisting of nitrogen, oxygen and sulfur, the heterocyclic group being unsubstituted or substituted; R.sup.3 is hydrogen, a C.sub.1 -C.sub.6 alkyl, cyano, or --R.sup.5 ; X is oxygen or sulfur; A is a 1,4-piperazin-1,4-diyl or a 1,4-homopiperazin-1,4-diyl; B is a C.sub.1 -C.sub.6 alkylene, carbonyl, thiocarbonyl, sulfinyl or sulfonyl; and R.sup.4 is an unsubstituted or substituted phenyl group.Type: GrantFiled: October 7, 1994Date of Patent: September 24, 1996Assignee: Sankko Company, LimitedInventors: Norio Nakamura, Nobuyuki Ohkawa, Takeshi Oshima, Masaaki Miyamoto, Yasuteru Iijima
-
Patent number: 5527548Abstract: A method for promoting digestibility of a food product having an acid character which, when ingested, causes stimulation and hypersecretion of gastric and/or duodenum mucosae. The method comprises incorporating into the food product a sufficient amount of benzimidazole or a benzimidazole compound of the formula: ##STR1## where X and Y independently represent an alkyl group, a phenyl group or a halogen atom and n=1 to 4.Type: GrantFiled: January 13, 1995Date of Patent: June 18, 1996Inventor: Carlos Tyortyalian
-
Patent number: 5523303Abstract: The invention relates to novel, pharmaceutically active trisubstituted cycloalkane derivatives, a process for the preparation thereof and pharmaceutical compositions comprising the same. The invention also encompasses the use of the said cycloalkane derivatives for the treatment of diseases and for the preparation of pharmaceutical compositions suitable for the treatment of diseases.The compounds according to the invention are characterized by the general formula (I), ##STR1## wherein R represents hydrogen, C.sub.1-4 alkyl or hydroxyl,R.sup.1 stands for C.sub.1-12 alkyl,R.sup.2 and R.sup.3 each represents hydrogen, C.sub.1-12 alkyl or C.sub.2-12 alkenyl, orR.sup.2 and R.sup.3 together with the adjacent nitrogen atom form a 4- to 7-membered ring optionally comprising an oxygen, sulfur or a further nitrogen atom, which latter may carry a phenyl, benzyl or C.sub.1-4 alkyl substituent,R.sup.4 and R.sup.5 each stands for hydrogen, halogen or C.sub.Type: GrantFiled: April 11, 1994Date of Patent: June 4, 1996Assignee: Egis Gyogyszergyar Rt.Inventors: Judit Bajnogel, Gabor Blasko, Zoltan Budai, Andras Egyed, Marton Fekete, Erika Karaffa, Tibor Mezei, Klara Reiter nee Esses, Gyula Simig, Katalin Szemeredi, Eniko Szirt nee Kiszelly
-
Patent number: 5510382Abstract: The invention is related to the field of treating gastric and duodenal disorders and more specifically to the use of certain 13,14-dihydro-prostaglandin E derivatives, especially of PGE.sub.2, which are modified to contain a ring structure in the omega chain. The invention relates also to pharmaceutical compositions containing an active amount of these derivatives.Type: GrantFiled: May 6, 1993Date of Patent: April 23, 1996Assignee: Pharmacia ABInventors: Johan Stjernschantz, Bahram Resul
-
Patent number: 5506264Abstract: The present invention is concerned with the zinc tranexamate represented by the formula: ##STR1## or its pharmacologically acceptable organic acid salts. The zinc compounds of the present invention, when given in smaller doses than tranexamic acid and cetraxate hydrochloride, exhibit anti-inflammatory and anti-ulcer activities, and are tasteless and odorless, thus being easy to be administered; in particular, the organic acid salts are water-soluble and can be processed into the liquid dosage forms of injectable solution and liquid preparations for external uses.Type: GrantFiled: December 20, 1994Date of Patent: April 9, 1996Assignee: Zaidan Hojin Seisan Kaihatsu Kaguki KenkyushoInventors: Hajime Fujimura, Takahiro Yabuuchi, Teruo Tanaka
-
Patent number: 5484800Abstract: The present invention is directed to liquid medicinal suspension compositions for the administration of doses of active pharmaceutical agents such as H.sub.2 -antagonists. H.sub.2 -antagonists are known for their adverse taste and/or malodor and the claimed suspension functions to mask the adverse taste and odor of such active ingredients. Also disclosed are liquid medicinal compositions comprising the claimed suspension composition and the H.sub.2 -antagonist active ingredients.Type: GrantFiled: August 30, 1994Date of Patent: January 16, 1996Assignee: American Home Products CorporationInventors: Robert G. Blank, Annabelle Mogavero, Alexander Seabrook
-
Patent number: 5472695Abstract: The invention relates to the use of either an aqueous extract or an organic extract of the plant Thymus to prepare a pharmaceutical composition useful to inhibit the growth of Helicobacter pylori and the urease activity of Helicobacter pylori. In case of an aqueous extract, a minimum amount of 0.5 mg of the dry plant in the extract is required but the preferred amounts are above 1.2 mg. The aqueous extract may be used either as a drink, with or without additional ingredients, or transformed into a capsule or a paste. The invention also relates to in-vitro methods for inhibiting the growth of the urease activity of Helicobacter pylori.Type: GrantFiled: April 8, 1994Date of Patent: December 5, 1995Assignee: Technion Research and Development Foundation Ltd.Inventors: Itzhak Neeman, Mina Tabak, Robert Armon
-
Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface
Patent number: 5466680Abstract: The present invention relates to a method for enhancing white blood cell functioning and metabolism on a mucosal surface of a mammal. The present invention also relates to a method for treating or preventing a condition in a mammal caused by the presence of a disease-causing agent on a mucosal surface or a cutaneous surface wherein the disease-causing agent can be diminished by the actions of the white blood cells. The present invention yet also relates to a method for healing a wound of a mucosal or cutaneous surface. The present invention also relates to compositions for use in such methods.Type: GrantFiled: March 26, 1992Date of Patent: November 14, 1995Assignee: Cytologics, Inc.Inventor: Michael A. Rudy -
Patent number: 5464620Abstract: The invention relates to a pharmaceutical composition, which is useful in the treatment of gastrointestinal disorders, especially gastric ulcer, duodenal ulcer and gastritis. The pharmaceutical composition is composed of Rhizoma coptidis extract, Radix scutellariae extract, and Radix astragali extract. Processes for producing these components are provided.Type: GrantFiled: July 1, 1994Date of Patent: November 7, 1995Inventor: Xinxian Zhao
-
Patent number: 5417980Abstract: This invention relates to a pharmaceutical composition for treating the symptoms of overindulgence comprising an analgesic effective amount of acetaminophen or a non-steroidal anti-inflammatory drug and a gastric acid inhibiting effective amount of an H.sub.1 or H.sub.2 blocker, proton pump inhibitor or a combination thereof and methods of treating the symptoms of overindulgence comprising administering such pharmaceutical compositions.Type: GrantFiled: June 29, 1994Date of Patent: May 23, 1995Assignee: McNeil-PPC, Inc.Inventors: William J. Goldman, Thomas N. Gates
-
Patent number: 5407687Abstract: The present invention comprises a bi-layer, pharmaceutical tablet having one layer formulated for the immediate release (IR) of ranitidine and a second layer formulated for sustained release (SR) of ranitidine with the ratio of ranitidine in the IR layer to that in the SR in the range of from about 30:70 to about 60:40.Type: GrantFiled: February 22, 1994Date of Patent: April 18, 1995Assignee: Glaxo Inc.Inventors: Mark D. Coffin, Alan F. Parr
-
Patent number: 5401721Abstract: This invention describes pharmaceutical compositions and methods of treating ulcerating diseases of the gastrointestinal tract in mammals with an acid-resistant fibroblast growth factor compositions. Also described is the use of acid-resistant fibroblast growth factor compositions in the treatment of various other fibroblast growth factor-responsive conditions.Type: GrantFiled: April 3, 1992Date of Patent: March 28, 1995Assignees: Takeda Chemical Industries, Children's Medical CenterInventors: Moses J. Folkman, Koichi Kato
-
Patent number: 5401504Abstract: Method of promoting healing of a wound by administering turmeric to a patient afflicted with the wound.Type: GrantFiled: December 28, 1993Date of Patent: March 28, 1995Assignee: University of Mississippi Medical CenterInventors: Suman K. Das, Hari Har P. Cohly
-
Patent number: 5399584Abstract: The subject invention relates to methods for preventing or treating damage to the mucosal lining of the gastrointestinal tract of a human or lower animal by administering a safe and effective amount of a compound having the structure: ##STR1## wherein X and Y are each independently selected from O and S; R.sup.1, R.sup.2 and R.sup.3 are each independently selected from hydrogen, hydroxy, halo, unsubstituted or monosubstituted straight or branched C.sub.1 -C.sub.4 alkanyl, and unsubstituted or substituted straight or branched C.sub.1 -C.sub.4 alkanoxy; and each of R.sup.4, R.sup.5, R.sup.6 and R.sup.7 is hydrogen or, if one or more of R.sup.1, R.sup.2 and R.sup.3 is other than hydrogen, each of R.sup.4, R.sup.5, R.sup.6 and R.sup.7 is selected from hydrogen, halo, trifluoromethyl, and unsubstituted straight or branched C.sub.1 -C.sub.4 alkanyl.Type: GrantFiled: February 10, 1993Date of Patent: March 21, 1995Assignee: The Procter & Gamble CompanyInventors: Jeffrey J. Ares, Sunil V. Kakodkar, Gary R. Kelm, Peter D. Murray, Jared L. Randall, Candice L. Slough
-
Patent number: 5380748Abstract: A trialkylamine derivative represented by the formula (1) or a pharmaceutically acceptable salt thereof: ##STR1## wherein R.sup.1 and R.sup.2 may be the same or different from each other and each represents lower alkyl;R.sup.3, R.sup.4 and R.sup.5 may be the same or different from one another and each represents hydrogen, lower alkyl, lower alkoxy, lower alkoxycarbonyl or halogen;R.sup.6 and R.sup.7 may be the same or different from each other and each represents hydrogen or lower alkyl;R.sup.8 represents hydrogen, lower alkyl, lower alkoxy or halogen;X represents oxygen, sulfur, --CH.dbd.N-- or --CH.dbd.CH--;Y represents oxygen, sulfur, methylene, N--R.sup.11 (wherein R.sup.11 represents lower alkyl), SO or SO.sub.2 ;Z represents --OCO(CH.sub.2).sub.p .about. or --OCH.sub.2 (CH.sub.2).sub.p .about. (wherein p represents a number of 0 to 4 and symbol .about.Type: GrantFiled: August 30, 1993Date of Patent: January 10, 1995Assignee: Zeria Pharmaceutical Co., Ltd.Inventors: Yoshiaki Muto, Hiromi Ichikawa, Kuniyoshi Ogura, Kyoji Chaki, Masao Seiki, Toshihiko Takemasa
-
Patent number: 5300493Abstract: Acidic polysaccharide esters containing carboxylic groups are useful for protecting against and curing ulcers of the gastro-enteric system. These esters include choline esters with acidic polysaccharide selected from the group consisting of hyaluronic acid, alginic acid, gellan, oxidized cellulose, oxidized chitin, carboxy-hydrocarbyl-cellulose, carboxy-hydrocarbyl-starch and carboxy-hydrocarbyl-chitin, wherein the term hydrocarbyl means the residue of a hydrocarbon selected from the group consisting of by alkyl, aralkyl and cycloalkyl.Type: GrantFiled: September 16, 1992Date of Patent: April 5, 1994Assignee: Fidia S.p.A.Inventors: Aurelio Romeo, Gino Toffano, Lanfranco Callegaro
-
Patent number: 5296469Abstract: The diosmin heptakis (hydrogensulfate) aluminum complex is described, as l as its preparation procedure, characterized by reacting one mole of diosmin with seven moles of a sulfating agent in a dry medium and treatment with an aqueous aluminum hydroxycloride solution of the diosmin heptakis (hydrogensulfate) sodium salt thus obtained. A description of pharmacological assays carried out to confirm the cytoprotective action of the product is included.Type: GrantFiled: February 25, 1993Date of Patent: March 22, 1994Assignee: Fabrica Espanola de Productos Quimicos y Farmaceuticos, S.A.Inventors: Aurelio Orjales-Venero, Ramon Mosquera-Pestana
-
Patent number: 5260071Abstract: Medical materials for use in treating maladies in living beings, such as ulcers and other conditions of the digestive tract. In one form, a container is provided for a medication which container also contains an adhesive material which is operatively released from the container or exposed at the surface thereof upon biodegradation or dissolution of a protective coating or wall portion of the container under the effects of fluid in the digestive tract in which the container is exposed, such as by swallowing, to permit such adhesive to temporarily bond and retain the container at a select location in the digestive tract so that it may slowly release its contents thereafter to a select portion of the digestive tract. In another form, a multitude of microcapsules, each containing a small quantity of medication, is mixed with an adhesive material, such as a sucralfate other material which may be swallowed as a tablet or dissolved in a liquid such as water.Type: GrantFiled: November 12, 1991Date of Patent: November 9, 1993Inventor: Jerome H. Lemelson
-
Patent number: 5260333Abstract: Pharmaceutical composition and process for administering NSAIDs with a combination of beta-adrenergic agonist and certain H.sub.1 -and H.sub.2 -receptor blockers which protect against injury to the gastrointestinal tract. Said composition being terbutaline, diphenhydramine and ranitidine.Type: GrantFiled: April 9, 1992Date of Patent: November 9, 1993Assignee: Bristol Myers Squibb CompanyInventors: Alison B. Lukacsko, Joseph J. Piala
-
Patent number: 5256684Abstract: Methods, for the treatment of humans and lower animal subjects having a gastrointestinal disorder, comprising administering bismuth and administering an antimicrobial. From about 50 to about 5000 milligrams of bismuth are administered, per day, for from 3 to 56 days. A safe and effective amount of antimicrobial is administered for from 1 to 21 days. Preferred processes also include a step for performing a diagnostic test on the subject for detection of a campylobacter-like organism infection of the subject. The invention also provides compositions containing a safe and effective amount of bismuth and a safe and effective amount of antimicrobial.Type: GrantFiled: July 26, 1991Date of Patent: October 26, 1993Assignee: The Procter & Gamble CompanyInventor: Barry J. Marshall
-
Patent number: 5250300Abstract: A liquid internal medicine for domestic animals contains only an extract from stems of natural Stevia plants. The medicine is effective for curing disorders of the digestive organs of domestic animals and for improving the physical constitution of domestic animals to further result in improvement of meat quality, milk quality and hair gloss of domestic animals and promotion of the estrous cycle and their establishment of the menstrual function. The medicine contains a liquid obtained by fermenting a concentrate of an extract from Stevia stems, and is administered to domestic animals as is or after dilution. As the medicine contains only the natural component, it is free of any side effects when applied to domestic animals.Type: GrantFiled: January 28, 1992Date of Patent: October 5, 1993Assignees: Fumio Dozono, Naohiko SatoInventor: Fumio Dozono
-
Patent number: 5250301Abstract: A liquid internal medicine contains only an extract from stems of natural Stevia plants. The medicine is particularly effective for curing disorders of the digestive organs. The medicine contains a liquid obtained by fermenting a concentrate of an extract from Stevia stems, and is administered to patients as is or after dilution. As the medicine contains only the natural component, it is free of any side effects when applied to patients.Type: GrantFiled: January 28, 1992Date of Patent: October 5, 1993Assignees: Fumio Dozono, Naohiko SatoInventor: Fumio Dozono
-
Patent number: 5234910Abstract: An acid inhibitor of bacterial origin which is effective in inhibiting acid secretion from gastric parietal cells; a method of producing this acid inhibitor; a method of administering the acid inhibitor to reduce acid secretion by parietal cells; and a therapeutic composition, which includes the acid inhibitor, for use in the method. In particular, the invention relates to a protein produced by gastric Spirilla, such as Helicobacter pylori (H. pylori), which is effective in inhibiting acid secretion by parietal cells and, thus, can be used in the treatment of peptic ulcer disease and other conditions of the gastroduodenal tract in which there is a tendency for ulceration.Type: GrantFiled: October 10, 1990Date of Patent: August 10, 1993Assignee: University HospitalInventor: David R. Cave
-
Patent number: 5229380Abstract: The invention relates to a method of arresting and treating duodenal and gastric ulcers, and chronic gastritis comprising administering an effective amount of [4S(4.alpha.,4a.alpha.,5a.alpha.,12a.alpha.)]-4,7-bis (dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12, 2a-tetrahydroxy-1,11-dioxo-2-napthacenecarboxymide monohydrochloride.Type: GrantFiled: June 28, 1991Date of Patent: July 20, 1993Inventor: Richard Y. Harris
-
Patent number: 5225445Abstract: Phenethanolamine derivatives are disclosed of formula ##STR1## wherein m is 2 to 8; n is 1 to 7 provided that m+n is 4 to 12;Ar is phenyl or phenyl substituted by one or two halogen atoms, alkyl or alkoxy groups or by an alkylenedioxy group;R.sup.1 and R.sup.2 are hydrogen or alkyl provided that the sum total of carbon atoms in R.sup.1 and R.sup.2 is not more than 4;and the physiologically acceptable salts and solvates thereof.The compounds have a selective stimulant action at .beta..sub.2 -adrenoreceptors and may be used inter alia in the treatment of diseases associated with reversible airways obstructions such as asthma and chronic bronchitis. The compounds may be formulated in conventional manner as pharmaceutical compositions with physiologically acceptable carriers or excipients.The compounds may be prepared, for example by alkylation of an amine: ##STR2## where R.sup.3, R.sup.5 and R.sup.6 is hydrogen or a protecting group, followed by removal of any protecting group.Type: GrantFiled: February 19, 1992Date of Patent: July 6, 1993Assignee: Glaxo Group Ltd.Inventors: Ian F. Skidmore, Lawrence H. C. Lunts, Harry Finch, Alan Naylor
-
Patent number: 5223521Abstract: The invention relates to a method of preventing or treating gastrointestinal ulcer disease and microvascular injury in a mammal comprising administering to said mammal a pyrazole derivative alone or in combination with an ulcerogenic agent. The invention further relates to pharmaceutical compositions comprising a pyrazole derivative in combination with an ulcerogenic therapeutic agent to inhibit or prevent the ulcerogenic effect of that agent.Type: GrantFiled: March 8, 1991Date of Patent: June 29, 1993Assignee: Brigham and Women's HospitalInventor: Sandor Szabo
-
Patent number: 5223537Abstract: The invention is related to the field of treating gastric and duodenal disorders and more specifically to the use of certain 13,14-dihydro-prostaglandin E derivatives, especially of PGE.sub.2, which are modified to contain a ring structure in the omega chain. The invention relates also to pharmaceutical compositions containing an active amount of these derivatives.Type: GrantFiled: July 23, 1991Date of Patent: June 29, 1993Assignee: Kabi Pharmacia ABInventors: Johan Stjernschantz, Bahram Resul
-
Patent number: 5219870Abstract: This invention relates to omeprazole compositions designed for administration in the rectum, wherein said compositions comprise omeprazole, an active ingredient, a mixture of polyethylene glycols having molecular weights 1,000, 1,540, 4,000 and/or 6,000 or a mixture of adeps solidus and sodium laurylsulfate and a soluble, basic amino acid selected from arginine, lysine or histidine.Type: GrantFiled: February 27, 1991Date of Patent: June 15, 1993Inventor: Kwang Sik Kim
-
Patent number: 5219563Abstract: The bitter taste of ranitidine may be masked by forming an adsorbate with a synthetic cation exchange resin. The adsorbate is particularly suitable for use in pharmaceutical compositions for oral administration such as chewable or suckable tablets, granules and aqueous or non-aqueous suspensions.Type: GrantFiled: February 28, 1992Date of Patent: June 15, 1993Assignee: Glaxo Group LimitedInventors: Stephen J. Douglas, Fiona R. Bird
-
Patent number: 5204118Abstract: This invention relates to a pharmaceutical composition for treating the symptoms of overidulgence comprising an analgesic effective amount of acetaminophen or a non-steroidal anti-inflammatory drug and a gastric acid inhibiting effective amount of an H.sub.1 or H.sub.2 blocker, proton pump inhibitor or a combination thereof and methods of treating the symptoms of overindulgence comprising administering such pharmaceutical compositions.Type: GrantFiled: April 29, 1992Date of Patent: April 20, 1993Assignee: McNeil-PPC, Inc.Inventors: William J. Goldman, Thomas N. Gates
-
Patent number: 5175147Abstract: This invention describes pharmaceutical compositions and methods of treating ulcerating diseases of the gastrointestinal tract in mammals with an acid-resistant fibroblast growth factor compositions. Also described is the use of acid-resistant fibroblast growth factor compositions in the treatment of various other fibroblast growth factor-responsive conditions.Type: GrantFiled: July 20, 1989Date of Patent: December 29, 1992Assignees: Takeda Chemical Industries, Ltd, Children's Medical Center CorporationInventors: Moses J. Folkman, Koichi Kato
-
Patent number: 5171753Abstract: Derivatives of 2-amino-1-phenylethanol were prepared from substituted amines and benzoin, stilbene oxide or styrene oxide to give compounds of Formula: ##STR1## where R is H or (un)substituted phenyl and C is a linking group or terminal group. The compounds of this invention can inhibit ulceration in in-vivo studies in rats.Type: GrantFiled: May 15, 1991Date of Patent: December 15, 1992Assignee: A. H. Robins Company, IncorporatedInventors: Harry R. Munson, Jr., Robert F. Boswell
-
Patent number: 5164379Abstract: Complexes of sucralfate with alpha cyclodextrin, beta cyclodextrin, gamma cyclodextrin or 2-hydroxypropyl beta cyclodextrin are disclosed. Also disclosed are a process for producing complexes and compositions and a method for reducing gastric injury, employing the complexes.Type: GrantFiled: July 15, 1991Date of Patent: November 17, 1992Assignee: Bristol-Myers CompanyInventors: Randy J. Koslo, Vincent J. Farina
-
Patent number: 5155125Abstract: A therapeutic preparation for ulcers contains as a primary ingredient a compound having an aldose reductase inhibitory activity and can accelerate dermal metabolism. That compound may be d-6-fluoro-2,3-dihydro-2',5'-dioxo-spiro [4H-1-benzopyran-4,4'-imidazolidine]-2-carboxyamide, d-2-chloromethyl-6-fluoro-2,3-dihydro-spiro [4H-1-benzopyran-4,4'-imidazolidine]-2',5'-dione and d-2-bromomethyl-6-fluoro-2,3-dihydro-spiro [4H-1-benzopyran-4,4'-imidazolidine]-2',5'-dione.Type: GrantFiled: October 22, 1990Date of Patent: October 13, 1992Assignee: Sanwa Kagaku Kenkyusho Co., Ltd.Inventors: Kiichi Sawai, Masayasu Kurono, Kazumasa Nakano, Makoto Sato, Noboru Kuboyama, Takashi Ito, Yoshiya Kondo
-
Patent number: 5149702Abstract: Provided are cycloheptenopyridine derivatives represented by the general formula ##STR1## [wherein R represents a hydrogen atom or lower alkyl group; R.sup.1 represents a hydrogen atom, halogen atom, lower cycloalkoxy group, amido group, substituted phenoxy group, substituted benzyloxy group, lower alkoxy group optionally containing halogen atoms(s), nitro group, hydroxyl group, lower alkenyloxy group, lower alkylthio group, or a group--NR.sup.4 R.sup.5 (wherein R.sup.4 and R.sup.5 may be the same or different and each represent a hydrogen atom or lower alkyl group, or R.sup.4 and R.sup.5 mutually combine together with the nitrogen atom adjacent thereto to form a 5- or 6-membered heterocyclic group); R.sup.2 represents a hydrogen atom, halogen atom, lower alkyl group optionally containing a halogen atom, lower alkoxy group optionally containing a halogen atom, hydroxyl group, acyl group, lower alkoxycarbonyl group, nitro group or amino group; R.sup.Type: GrantFiled: November 27, 1990Date of Patent: September 22, 1992Assignee: Toa Eiyo Ltd.Inventors: Shin-ichi Yamada, Takao Goto, Rie Yorita, Eizi Shimanuki, Takaji Yamaguchi, Kentaro Kogi, Senichi Narita
-
Patent number: 5126375Abstract: Phenethanolamine derivatives are disclosed of formula ##STR1## wherein m is 2 to 8; n is 1 to 7 provided that m+n is 4 to 12;Ar is phenyl or phenyl substituted by one or two halogen atoms, alkyl or alkoxy groups or by an alkylenedioxy group;R.sup.1 and R.sup.2 are hydrogen or alkyl provided that the sum total of carbon atoms in R.sup.1 and R.sup.2 is not more than 4; and the physiologically acceptable salts and solvates thereof.The compounds have a selective stimulant action at .beta..sub.2 -adrenoreceptors and may be used inter alia in the treatment of diseases associated with reversible airways obstructions such as asthma and chronic bronchitis. The compounds may be formulated in conventional manner as pharmaceutical compositions with physiologically acceptable carriers or excipients.The compounds may be prepared, for example by alkylation of an amine: ##STR2## where R.sup.3, R.sup.5 and R.sup.6 is hydrogen or a protecting group, followed by removal of any protecting group.Type: GrantFiled: November 29, 1990Date of Patent: June 30, 1992Assignee: Glaxo Group Ltd.Inventors: Ian F. Skidmore, Lawrence H. C. Lunts, Harry Finch, Alan Naylor
-
Patent number: 5120533Abstract: Dimethylpolysiloxane is effective in the treatment of ulcers of the gastrointestinal tract.Type: GrantFiled: May 24, 1990Date of Patent: June 9, 1992Assignee: Steigerwald Arzneimittelwerk GmbHInventors: Alfred Schmidt, Hans-Jurgen Upmeyer
-
Patent number: 5091547Abstract: A pharmaceutical phenylacetic acid derivative of the following formula (I): ##STR1## with the process of obtention which includes reacting 2-(2,6-dichloroaniline)-phenylacetic acid with zinc oxide, zinc hydroxides, zinc carbonates or zinc salts or reacting an ammonium salt, an alkali metal salt or an alkaline earth metal salt of 2-(2,6-dichloroaniline)-phenylacetic acid with a zinc salt, e.g. zinc chloride, in a nonpolar solvent. The compound of formula I is novel and has improved pharmaceutical properties in anti-inflammatory preparations.Type: GrantFiled: May 17, 1990Date of Patent: February 25, 1992Assignee: Laboratorias Vinas, S.A.Inventor: Antonio Buxade
-
Patent number: 5091422Abstract: Phenethanolamine derivatives are disclosed of formula ##STR1## wherein m is 2 to 8;n is 1 to 7 provided that m+n is 4 to 12;Ar is phenyl or phenyl substituted by one or two halogen atoms, alkyl or alkoxy groups or by an alkylenedioxy group;R.sup.1 and R.sup.2 are hydrogen or alkyl provided that the sum total of carbon atoms in R.sup.1 and R.sup.2 is not more than 4;and the physiologically acceptable salts and solvates thereof.The compounds have a selective stimulant action at B.sub.2 -adrenoreceptors and may be used inter alia in the treatment of diseases associated with reversible airways obstructions such as asthma and chronic bronchitis. The compounds may be formulated in conventional manner as pharmaceutical compositions with physiologically acceptable carriers or excipients.The compounds may be prepared, for example by alkylation of an amine: ##STR2## where R.sup.3, R.sup.5 and R.sup.6 is hydrogen or a protecting group, followed by removal of any protecting group.Type: GrantFiled: June 21, 1990Date of Patent: February 25, 1992Assignee: Glaxo Group LimitedInventors: Ian F. Skidmore, Lawrence H. C. Lunts, Harry Finch, Alan Naylor
-
Patent number: 5089475Abstract: The invention relates to a method of treating pulmonary dysfunction in a mammal comprising administration of growth hormone to said mammal. In one embodiment wherein the pulmonary dysfunction results in ventilator dependency, the use of the method of this invention promotes the withdrawal of mechanical ventilatory support.Type: GrantFiled: February 7, 1989Date of Patent: February 18, 1992Assignee: Brigham and Women's HospitalInventor: Douglas W. Wilmore
-
Patent number: 5089639Abstract: N-Cycloalkylalkylamines of formula I: ##STR1## in which: R1 is phenyl which is optionally mono-, di- or trisubstituted by halogens or lower alkyl, haloalkyl or lower alkoxy radicals, or is an aromatic heterocyclic radical having 5 to 7 chain members, in which the hetero atom is nitrogen, oxygen or sulphur,R2 is lower alkyl,R3 is hydrogen or lower alkyl,m has the value of 1 or 2,R4 is cycloalkyl --CH(CH2)n, in which a carbon atom may carry a radical Rx, which is lower alkyl or phenyl; and in which n has the values from 2 to 5,R5 is phenyl, which can be mono-, di- or trisubstituted by halogens or by lower alkoxy radicals, andQ represents an ethylene-1,2-diyl group --CH.dbd.Type: GrantFiled: January 24, 1991Date of Patent: February 18, 1992Assignee: Jouveinal S.A.Inventors: Gilbert G. Aubard, Alain P. Calvet, Jean-Pierre Defaux, Claude J. Gouret, Agnes M. Grouhel, Henry L. Jacobelli, Jean-Louis Junien, Xavier B. Pascaud, Francois F. Roman, James P. Hudspeth, Yuan Lin
-
Patent number: 5069904Abstract: A method of using nicotine in the treatment of various conditions susceptible to alleviation by nicotine therapy such as disease states characterized by reduced central cholinergic function. Nicotine is administered to a subject initially having a blood supply substantially free of nicotine at a dose and for a period sufficient to allow the subject to tolerate the dose and thereafter increasing the dose of nicotine at intervals until a therapeutic dose is achieved. Smokers may also benefit from the treatment regimen.Type: GrantFiled: January 5, 1990Date of Patent: December 3, 1991Assignee: Elan Corporation, PLCInventor: Joseph G. Masterson
-
Patent number: 5066496Abstract: Ganglioside mixtures and/or lipid mixtures e.g. from brain and omentum, are found to be effective to treat peptic ulcers.Type: GrantFiled: August 3, 1988Date of Patent: November 19, 1991Assignees: Angio-Medical Corporation, Trustees of Boston UniversityInventors: Sandor Szabo, Meryl S. A. Rubin, Michael Klibaner, Ahmad R. Kamarei, Robert S. Sinn, Nicholas Catsimpoolas
-
Patent number: 5039699Abstract: An anti-peptic ulcer agent comprising (a) a powdery material which includes tocopheryl retinoate, light silicic anhydride, and an antioxidant; (b) a low substituted hydroxypropylcellulose; and (c) polyvinylpyrrolidone which is orally administrable.Type: GrantFiled: March 27, 1989Date of Patent: August 13, 1991Assignee: Lederle (Japan), Ltd.Inventors: Masaaki Kurihara, Keiichiro Ohta
-
Patent number: 5034419Abstract: N-Cycloalkylalkylamines of formula I: ##STR1## in which: R1 is phenyl which is optionally mono-, di- or trisubstituted by halogens or lower alkyl, haloalkyl or lower alkoxy radicals, or is an aromatic heterocyclic radical having 5 to 7 chain members, in which the hetero atom is nitrogen, oxygen or sulphur,R2 is lower alkyl,R3 is hydrogen or lower alkyl,m has the value of 1 or 2,R4 is cycloalkyl --CH(CH2)n, in which a carbon atom may carry a radical Rx, which is lower alkyl or phenyl; and in which n has the values from 2 to 5,R5 is phenyl, which can be mono-, di- or trisubstituted by halogens or by lower alkoxy radicals, andQ represents an ethylene-1,2-diyl group --CH.dbd.Type: GrantFiled: February 26, 1990Date of Patent: July 23, 1991Assignee: L'OrealInventors: Gilbert G. Aubard, Alain P. Calvet, Jean-Pierre DeFaux, Claude J. Gouret, Agnes M. Grouhel, Henry L. Jacobelli, Jean-Louis Junien, Xavier Pascaud, Francois F. Roman, James P. Hudspeth, Yuan Lin